PTGX · XBRL financial data

Protagonist Therapeutics financial statements, every fiscal year

The same tables from 7 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (PTGX's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Research and development	74,506	126,006	126,215	120,161	138,128	159,290
General and administrative	18,638	27,196	31,739	33,491	43,462	44,853
Total operating expenses	93,144	153,202	157,954	153,652	181,590	204,143
Operating income (loss)	(64,516)	(125,845)	(131,373)	(93,652)	252,843	(158,127)
Interest income	900	443	4,060	14,898	26,315	28,789
Interest expense	598	—	—	—	—	—
Other income (expense)	(46)	(149)	(80)	(201)	250	27
Income tax expense (benefit)	1,305	0	0	0	4,220	838
Net income (loss)	(66,150)	(125,551)	(127,393)	(78,955)	275,188	(130,149)
Earnings per share, basic USD per share	(1.92)	(2.71)	(2.60)	(1.39)	4.47	(2.05)
Earnings per share, diluted USD per share	(1.92)	(2.71)	(2.60)	(1.39)	4.23	(2.05)
Weighted average shares, basic thousands of shares	34,396	46,323	49,042	56,764	61,567	63,573
Weighted average shares, diluted thousands of shares	34,396	46,323	49,042	56,764	65,078	63,573

Fiscal years (PTGX's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	117,358	123,665	125,744	186,727	97,249	128,390
Marketable securities	188,451	203,235	111,611	154,890	321,664	438,974
Marketable securities, non-current	2,000	—	0	—	140,252	78,638
Prepaid and other current assets	6,277	9,478	5,712	3,960	7,728	10,089
Total current assets	315,606	340,736	243,077	355,577	591,641	577,574
Property and equipment, net	1,462	1,798	1,565	1,195	3,190	3,860
Right-of-use asset	4,950	4,936	3,061	954	9,417	7,829
Total assets	324,468	347,695	247,928	357,951	744,725	668,188
Accounts payable	3,075	1,600	3,640	772	1,615	5,339
Accrued liabilities	18,498	37,716	24,955	19,358	23,693	28,269
Total current liabilities	40,241	44,016	31,179	21,274	47,398	45,441
Lease liability, non-current	4,500	3,658	1,141	—	10,356	8,040
Total liabilities	44,862	47,674	32,320	21,274	69,430	53,481
Accumulated deficit	(283,811)	(409,362)	(536,755)	(615,710)	(340,522)	(470,671)
Total stockholders' equity	279,606	300,021	215,608	336,677	675,295	614,707
Total liabilities and equity	324,468	347,695	247,928	357,951	744,725	668,188
Common shares outstanding (cover page) thousands of shares	43,808	48,414	51,275	58,275	61,384	63,809

Fiscal years (PTGX's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(66,150)	(125,551)	(127,393)	(78,955)	275,188	(130,149)
Stock-based compensation	7,899	16,395	24,202	29,293	37,554	45,974
Depreciation and amortization	789	813	1,034	977	826	1,280
Net cash from operating activities	(72,484)	(107,865)	(108,137)	(70,236)	184,152	57,671
Purchases of property and equipment	471	1,101	795	609	1,355	1,590
Net cash from investing activities	(90,965)	(15,860)	91,468	(39,258)	(299,483)	(49,332)
Proceeds from issuing common stock	213,303	123,829	—	107,798	—	—
Repayments of long-term debt	10,524	—	—	—	—	—
Net cash from financing activities	247,626	129,923	18,838	170,477	25,853	22,864
Net change in cash	84,352	6,072	2,079	60,983	(89,478)	31,203

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Protagonist Therapeutics	420,078	213,475	219,052*	64.7M	—	Q2 FY26 10-QJun 30, 2026
Prestige Consumer Healthcare	89,127	265,710	70,788	47.4M	—	Q1 FY27 10-QJun 30, 2026
Viking Therapeutics	677,609	0	(138,194)*	127.5M	7.6 quarters	Q3 FY26 10-QSep 30, 2026
Catalyst Pharmaceuticals	755,859	149,390	59,587	122.4M	—	Q1 FY26 10-QMar 31, 2026
Cytokinetics	203,433	47,557	not reported	139.3M	—	Q3 FY26 10-QSep 30, 2026
TG Therapeutics	482,575	240,335	39,263*	153.1M	—	Q2 FY26 10-QJun 30, 2026
Summit Therapeutics	150,811	not reported	not reported	799.8M	—	Q3 FY26 10-QSep 30, 2026
Ultragenyx Pharmaceutical	150,000	173,000	(43,000)*	101.9M	2.3 quarters	Q3 FY26 10-QSep 30, 2026
Avidity Biosciences	382,517	860*	(169,773)*	155.1M	2.3 quarters	Q4 FY25 10-KDec 31, 2025

Not investment advice. Not affiliated with the U.S. SEC.